In contrast to what was previously believed, a key protein implicated in Parkinson’s disease — called Nurr1 — can be modulated using naturally existing molecules or engineered small molecules to restore dopamine production in brain cells, according to a study. Conducted by researchers from the University of California San…
Researchers in Australia are planning to test therapies already being used in other inflammatory conditions, as well as new compounds, for their potential to block brain inflammation and halt Parkinson’s disease progression. Conducted by researchers at The University of Queensland (UQ) in Australia, the study, “Pharmacological…
To further support its quest to advance a new therapy for Parkinson’s disease and related disorders, Inhibikase Therapeutics has added three leading researchers to its Scientific Advisory Board (SAB). The pharmaceutical company is developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases. Its pipeline…
The National Institutes of Health (NIH) has granted a Michigan State University scientist $5 million to study a possible link between pesticides, a diminished sense of smell, and early symptoms of diseases such as Parkinson’s among older farmers. The investigator is Honglei Chen, MD, PhD, a professor of…
Antiparkinsonian medicines may allow patients with mild to moderate Parkinson’s disease to experience freedom of movement, which could be confused with balance issues if measured by traditional postural stability testing, researchers suggest. Their findings were published in the study, “The influence of dopaminergic medication on…
New preclinical data have shown for the first time the underlying mechanisms mediating the therapeutic activity of Anavex 2-73, an investigational therapy being evaluated for the treatment of neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). Anavex Life Sciences’ investigational activator of the sigma-1 receptor…
A protein called osteonectin may be implicated in Parkinson’s and other neurodegenerative diseases, according to a computer-based analysis. The study, “In silico method for identification of novel copper and iron metabolism proteins in various neurodegenerative disorders,” was published in the journal NeuroToxicology. Excessive production of copper and…
Antiparkinsonian medicines may cause Parkinson’s patients to develop abnormal sensitivity to temperature, touch and pain, according to a recent study. The study, “Quantitative Sensory Testing (QST) in Drug-Naïve Patients with Parkinson’s Disease” was published in the Journal of Parkinson’s Disease. The somatosensory system is composed of neurons that…
Exercise has the potential to improve cognitive function in people with Parkinson’s disease, and has positive effects on motor symptoms, according to a recent literature review study. “The potential of exercise to improve motor and non-motor symptoms is promising and may help to decelerate disease progression in individuals affected by…
Symptoms of apathy and depression are more frequent and severe in Parkinson’s patients with rapid eye movement sleep behavior disorder (RBD) than in patients without this disorder, according to a study. Findings also showed that women with Parkinson’s and RBD are more likely to experience apathy than men.
Get regular updates to your inbox.
